TY  - JOUR
AU  - Jansen, Philipp
AU  - Galetzka, Wolfgang
AU  - Thielmann, Carl M
AU  - Murali, Rajmohan
AU  - Zaremba, Anne
AU  - Standl, Fabian
AU  - Lodde, Georg
AU  - Möller, Inga
AU  - Sucker, Antje
AU  - Paschen, Annette
AU  - Hadaschik, Eva
AU  - Ugurel, Selma
AU  - Zimmer, Lisa
AU  - Livingstone, Elisabeth
AU  - Schadendorf, Dirk
AU  - Stang, Andreas
AU  - Griewank, Klaus G
TI  - pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy.
JO  - European journal of cancer
VL  - 220
SN  - 0959-8049
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-00521
SP  - 115337
PY  - 2025
AB  - TERT promoter mutations are the most prevalent mutations in melanoma. In this study, we investigated clinical characteristics and survival after first line therapies in a cohort of melanoma patients with known TERT promoter (pTERT) mutation status.Sequencing data from 2013 to 2021 covering 29 genes and the pTERT status was assessed and 774 melanomas patients with known pTERT status and clinical data were analyzed. Progression free survival (PFS) and overall survival (OS) of 374 melanoma patients in AJCC-stage IV who received first-line immune checkpoint inhibitors (ICI, anti-CTLA4 /anti-PD1 combination therapy or anti-PD1 monotherapy) or targeted therapy (TT) were assessed applying Cox uni-/ multivariable analyses and Kaplan-Meier curves.The cohort included 573 cutaneous, 69 mucosal, 37 acral and 95 MUP (melanomas of unknown primary) melanoma patients with a median observational time from first diagnosis to patient death or censoring of 38.5 months. TERT promoter mutations were identified in 476 melanomas (61.5 
KW  - Immune therapy (Other)
KW  - Melanoma (Other)
KW  - Mutational profiling (Other)
KW  - PTERT (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40056560
DO  - DOI:10.1016/j.ejca.2025.115337
UR  - https://inrepo02.dkfz.de/record/299580
ER  -